A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Conditions: HER2-PositiveRecurrent or Metastatic Breast Cancer Interventions: Drug: SHR-A1811 Injection; Drug: SHR-A1811 Injection ； Pertuzumab Injection; Drug: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials